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Reply to the Editor:
We thank Pocar and colleagues for their
interest in our article regarding surgery for
acute type A aortic dissection in the setting
of stroke.1 We also acknowledge their re-
cent report about repairing acute type A
aortic dissection in patients with coma.2 As
was pointed out in their report, the use of
the Glasgow Coma Scale (GCS) to exclude
patients for type A aortic repair was not
relevant. Specifically, they noted that all 5
of their patients would have been consid-
ered severely brain injured (GCS  8)
based on the GCS alone. We do appreciate
and concur with this point and also con-
gratulate them for them for their results in
this very difficult subgroup of patients.
Although the GCS, the National Insti-
tutes of Health Stroke Scale (NIHSS), and
Rankin score for that matter may not be
completely applicable in the setting of
acute type A aortic dissection, we wanted
to analyze these patients with objective cri-
teria. We do believe that the NIHSS and the
Rankin score may be helpful, although this
study was not powered to demonstrate this.
Because we recommended that operative
repair was indicated in patients without
“neurologic devastation” or coma, we at-
tempted to provide some objective criteria
for this condition, hence the use of these
scales and scores. Regarding the 1 nonop-
erated patient who was considered neuro-
logically devastated, we acknowledge that
one cannot derive any conclusions in rela-
tion to defining neurologic devastation. In
fact, it was the appearance of the patient’s
computed tomography scan of the head,
which showed bilateral massive infarction,
that ultimately led to his nonoperative
course.
Prior to the results of this study, we
maintained that stroke was a relative con-
traindication to immediate repair for acute
type A aortic dissection. We have since
modified our approach and have become
more aggressive in repairing acute type A
aortic dissection in patients with stroke.
Our experience in patients with coma,
however, has been limited and thus we
continue to maintain a selective approach
in patients with coma and neurologic dev-
astation. We admit that GCS is not a good
measure of coma or neurologic devasta-
tion, and radiographic evaluation, in the
hemodynamically stable patient, may be
more helpful. How coma and neurologic
devastation are determined and whether or
not surgery is performed, however, should
be left ultimately to the neurologist and
operating surgeon, respectively.
Anthony L. Estrera, MD
Hazim J. Safi, MD
University of Texas Medical School
Houston, TX
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High-dose atorvastatin is associated
with impaired myocardial
angiogenesis in response to vascular
endothelial growth factor in
hypercholesterolemic swine:
Relevance to the human situation?
To the Editor:
We read with great interest the article by
Boodhwani and colleagues1 regarding the
impact of high-dose statin therapy on vas-
cular endothelial growth factor-A (VEGF-
A)–induced myocardial angiogenesis in a
hypercholesterolemic pig model of chronic
ischemia. This article demonstrated that
collateral-dependent myocardial perfusion
remained impaired in hypercholesterolemic
and atorvastatin-treated pigs in response to
additional treatment with VEGF-A relative
to a normocholesterolemic control group.
It concluded that a high-dose statin therapy
was not associated with improved myocar-
dial neovascularization. In that study,
however, the hypercholesterolemic pigs
were treated with an atorvastatin dosage
of 3 mg/(kg · d), which exceeds the
maximal possible dosage in patients (80
mg/d) by a factor of about 3.
To achieve at least moderate choles-
terol lowering, pigs need to be treated
with high-dose statins because of lesser
lipid-lowering potency and efficacy in
pigs relative to human beings.2 One must
remain aware, however, of the increased
risk of adverse events with extremely
high statin dosages. In their article,
Boodhwani and colleagues1 described a
clearly decreased capillary endothelial cell
density in the ischemic territory in the hyper-
cholesterolemic and atorvastatin-treated pigs
relative to the normocholesterolemic pigs and
even the untreated hypercholesterolemic an-
imals. To exclude the possibility that the hy-
percholesterolemic and atorvastatin-treated
pigs suffered potential toxic (cellular) side
effects of atorvastatin that might explain the
neovascularization impairment, the investi-
gators should have incorporated a control
group of normocholesterolemic pigs treated
with the same atorvastatin dosage. Moreover,
treatment of the hypercholesterolemic pigs
with lower atorvastatin dosages, more rel-
evant to the human situation, might dem-
onstrate whether there are potential dose-
dependent toxic cellular side effects.
Indeed, a recently published article by
Chade and associates3 indicates that statins
used in an intermediate (human) dosage in
pigs do lead to a stimulation of arteriogen-
esis. Furthermore, a retrospective clinical
study supports the view that intensified statin
treatment is associated with an improved arte-
riogenic response in human beings.4
Another piece of evidence for statin
overdose in the hypercholesterolemic pigs
of Boodhwani and colleagues1 might be the
observation of prolonged Akt activation in
the atorvastatin-treated pigs. Therefore, the
Akt downstream signal transduction path-
ways in endothelial cells might not any
longer be able to respond adequately to
other pathophysiologic stimuli. Indeed, it
has been demonstrated that a prolonged Akt
activation is associated with detrimental
cardiac effects in an ischemic mouse
model,5 as was even cited by Boodhwani
and colleagues1 in their article.
Taken together, we believe that it is not
appropriate to compare directly the arterio-
genic effects of high-dose statin treatment
in pigs and human beings in light of the
approximately 3-fold higher statin dosage
used in pigs.
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Reply to the Editor:
Statins are increasingly being used in pa-
tients with coronary disease. Recently,
there has been increasing evidence from
studies conducted in both in vitro and mu-
rine models that low-dose statins promote
angiogenesis and high-dose statins inhibit
it.1 The application of these findings to
patients is limited because of the lack of
translation of the experimental models to
the human setting. It is in this context that
we examined the in vivo effects of high-
dose atorvastatin in a clinically relevant
large animal model of chronic myocardial
ischemia and hypercholesterolemia. We
found that atorvastatin treatment did not
improve endogenous myocardial angiogen-
esis2 or response to growth factor therapy,3
despite improvement in endothelial func-
tion.
Czepluch and Waltenberger make the
important point that the dose of statins used
may be too high for clinical relevance and
indeed may be toxic. The first thing to note
is that, for initial toxicity studies, as much
as 80 mg/kg of atorvastatin was given to
beagle dogs without any observable ad-
verse effects,4 versus the dose of 3 mg/kg
used in our study. Second, when embarking
on these studies, our objective was to
choose a dose that would provide meaning-
ful reductions in total cholesterol and low-
density lipoprotein cholesterol in light of
the model of potent diet-induced hypercho-
lesterolemia being used. Finally, a number
of groups have demonstrated that Akt acti-
vation in response to atorvastatin exposure
occurs in a time-dependent manner; this
has been demonstrated in in vitro studies at
both low and high doses. We have shown
that this Akt activation also occurs in vivo
in the myocardium, and although it may
have detrimental effects, Akt activation is
not in and of itself indicative of statin over-
dose.
Czepluch and Waltenberger appropri-
ately point out that similar experiments
conducted in the setting of normocholester-
olemia and a lower, more clinically rele-
vant statin dose would help to validate our
findings. Indeed, we have recently per-
formed experiments examining a lower sta-
tin dose (1.5 mg/[kg · d], equivalent to 80
mg/d in humans), used routinely in the
clinical setting, in normocholesterolemic
swine (abstract presented at the American
Heart Association, Scientific Sessions
2005, manuscript currently under review).
We found that atorvastatin treatment (1.5
mg/[kg · d] for 20 weeks) was associated
with reduced collateral-dependent myocar-
dial perfusion and reduced endothelial cell
density in the ischemic territory of normo-
cholesterolemic swine relative to control
swine. These animals also demonstrated
impaired coronary microvessel relaxation
in response to growth factors (vascular en-
dothelial growth factor and fibroblast growth
factor) as well as increased myocardial ex-
pression of antiangiogenic protein (en-
dostatin). These findings provide substan-
tial support to the idea that high-dose
statins can impair the myocardial angio-
genic response.
In light of the mounting evidence from
in vitro and now in vivo large animal stud-
ies regarding the antiangiogenic effects of
high-dose statins, it is crucially important
to determine the relevance of these studies
to patients with coronary disease. It may be
that the metabolism of atorvastatin or the
signaling pathways leading to collateral
growth are different in pigs than in human
beings. Yet most preclinical research is
currently performed in this species. The
beneficial effects of statins on clinical out-
comes have been well demonstrated in
large clinical trials. One proposed mecha-
nism for their cholesterol-independent ef-
fects is plaque stabilization, which may
occur through the inhibition of plaque an-
giogenesis. There is also emerging recog-
nition, in the literature, of a possible benefit
of statins in reducing the incidence and
progression of neoplastic processes, which
may also be secondary to their antiangio-
genic effects. Finally, drug-eluting stents
clearly reduce the incidence of restenosis.
Yet there is recent evidence that collateral
growth is impaired by these stents.5 Thus,
the likelihood of vascular occlusion may be
less with these stents, but if it does occur,
there may not be as much collateral reserve,
leading to a high incidence of stent throm-
bosis–related death (40%).
The study of new vessel formation in
the myocardium is a challenging task that
is limited by currently available imaging
modalities (eg, angiography, nuclear imag-
ing, positron emission tomography). Thus
any definitive conclusions regarding the
applicability of these findings to the clini-
cal setting would first require rigorously
designed randomized clinical trials with
appropriately selected end points. These
studies would more clearly define the risks
and benefits of statins, which are increas-
ingly being used at high doses and for
indefinite periods. If proved in clinical
studies, the antiangiogenic properties of
statins would have to be incorporated in the
risk-benefit assessment for the initiation and
maintenance of statin therapy in patients with
coronary disease, in whom collateral vessel
formation can be a lifesaving process.
Munir Boodhwani, MD, MMSc
Frank W. Sellke, MD
Division of Cardiothoracic Surgery
Beth Israel Deaconess Medical Center
Harvard Medical School
Boston, Mass
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